SPR1020 / SciBrunch Therapeutics - LARVOL DELTA

An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=210 | Recruiting | Sponsor: Shanghai SciBrunch Therapeutics Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Platinum sensitive • Breast Cancer • HER2 Breast Cancer • Lung Cancer • Ovarian Cancer • Prostate Adenocarcinoma • Prostate Cancer • Small Cell Lung Cancer • Solid Tumor • BRCA • BRCA1 • BRCA2 • HER-2 • HRD • RAD51C • RAD51D

An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=210 | Not yet recruiting | Sponsor: Shanghai SciBrunch Therapeutics Co., Ltd.

First-in-human • New P1/2 trial • Platinum sensitive • Breast Cancer • HER2 Breast Cancer • Lung Cancer • Ovarian Cancer • Prostate Adenocarcinoma • Prostate Cancer • Small Cell Lung Cancer • Solid Tumor • BRCA • BRCA1 • BRCA2 • HER-2 • HRD • RAD51C • RAD51D